438 related articles for article (PubMed ID: 30231308)
41. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia.
Litzow MR
Am Soc Clin Oncol Educ Book; 2013; ():294-9. PubMed ID: 23714527
[TBL] [Abstract][Full Text] [Related]
42. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
[TBL] [Abstract][Full Text] [Related]
43. FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.
Jen EY; Xu Q; Schetter A; Przepiorka D; Shen YL; Roscoe D; Sridhara R; Deisseroth A; Philip R; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Jan; 25(2):473-477. PubMed ID: 30254079
[TBL] [Abstract][Full Text] [Related]
44. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression.
Jabbour E; Düll J; Yilmaz M; Khoury JD; Ravandi F; Jain N; Einsele H; Garcia-Manero G; Konopleva M; Short NJ; Thompson PA; Wierda W; Daver N; Cortes J; O'brien S; Kantarjian H; Topp MS
Am J Hematol; 2018 Mar; 93(3):371-374. PubMed ID: 29178361
[TBL] [Abstract][Full Text] [Related]
45. Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia.
Deak D; Pop C; Zimta AA; Jurj A; Ghiaur A; Pasca S; Teodorescu P; Dascalescu A; Antohe I; Ionescu B; Constantinescu C; Onaciu A; Munteanu R; Berindan-Neagoe I; Petrushev B; Turcas C; Iluta S; Selicean C; Zdrenghea M; Tanase A; Danaila C; Colita A; Colita A; Dima D; Coriu D; Einsele H; Tomuleasa C
Front Immunol; 2019; 10():2856. PubMed ID: 31921126
[No Abstract] [Full Text] [Related]
46. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
[TBL] [Abstract][Full Text] [Related]
47. Phase 1/2 study of blinatumomab in relapsed paediatric ALL.
Brower V
Lancet Oncol; 2016 Dec; 17(12):e525. PubMed ID: 27839960
[No Abstract] [Full Text] [Related]
48. Recent advances in the treatment of acute lymphoblastic leukemia.
Rafei H; Kantarjian HM; Jabbour EJ
Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
[TBL] [Abstract][Full Text] [Related]
49. Inotuzumab ozogamicin following allogeneic hematopoietic stem cell transplantation successfully rescued relapse of CD19-negative acute lymphoblastic leukemia after CAR-T cell therapy.
Kamitori T; Umeda K; Akazawa R; Iwai A; Obu S; Isobe K; Saida S; Kato I; Hiramatsu H; Taga T; Adachi S; Takita J
Pediatr Blood Cancer; 2021 May; 68(5):e28980. PubMed ID: 33619887
[No Abstract] [Full Text] [Related]
50. Should immunologic strategies be incorporated into frontline ALL therapy?
Rank CU; Stock W
Best Pract Res Clin Haematol; 2018 Dec; 31(4):367-372. PubMed ID: 30466749
[TBL] [Abstract][Full Text] [Related]
51. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
[TBL] [Abstract][Full Text] [Related]
52. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
[TBL] [Abstract][Full Text] [Related]
53. Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia.
Lyons KU; Gore L
Haematologica; 2024 Jun; 109(6):1668-1676. PubMed ID: 38832422
[TBL] [Abstract][Full Text] [Related]
54. Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP).
Fuster JL; Molinos-Quintana A; Fuentes C; Fernández JM; Velasco P; Pascual T; Rives S; Dapena JL; Sisinni L; López-Godino O; Palomo P; Villa-Alcázar M; Bautista F; González-Vicent M; López-Duarte M; García-Morín M; Ramos-Elbal E; Ramírez M;
Br J Haematol; 2020 Sep; 190(5):764-771. PubMed ID: 32314348
[TBL] [Abstract][Full Text] [Related]
55. Treatment of relapsed/refractory acute lymphoblastic leukemia.
Paul S; Rausch CR; Nasnas PE; Kantarjian H; Jabbour EJ
Clin Adv Hematol Oncol; 2019 Mar; 17(3):166-175. PubMed ID: 30969955
[TBL] [Abstract][Full Text] [Related]
56. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
57. Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia.
Gavralidis A; Brunner AM
Curr Hematol Malig Rep; 2020 Aug; 15(4):294-304. PubMed ID: 32445026
[TBL] [Abstract][Full Text] [Related]
58. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
Liu D; Zhao J; Song Y; Luo X; Yang T
J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
[TBL] [Abstract][Full Text] [Related]
59. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
60. SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.
Paul S; Rausch CR; Welch MA; Kantarjian HM; Jabbour EJ
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):471-479. PubMed ID: 31307896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
